Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Public ClinicalTrials.gov record NCT01382719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.
Study identification
- NCT ID
- NCT01382719
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 612 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2011 (Type not available)
- Primary completion
- Sep 2012 (Actual)
- Completion
- Sep 2012 (Actual)
- Last update posted
- Dec 18, 2014
2011 – 2012
United States locations
- U.S. sites
- 65
- U.S. states
- 30
- U.S. cities
- 63
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 56 | Birmingham | Alabama | 35209 | — |
| Site 26 | Huntsville | Alabama | 35801 | — |
| Site 64 | Mobile | Alabama | 36608 | — |
| Site 45 | Chandler | Arizona | 85224 | — |
| Site 39 | Phoenix | Arizona | 85032 | — |
| Site 25 | Tucson | Arizona | 85712 | — |
| Site 78 | Hot Springs | Arkansas | 71901 | — |
| Site 16 | Jonesboro | Arkansas | 72401 | — |
| Site 52 | National City | California | 91950 | — |
| Site 73 | Newport Beach | California | 92880 | — |
| Site 80 | Sacramento | California | 95821 | — |
| Site 12 | San Diego | California | 92120 | — |
| Site 37 | Denver | Colorado | 80218 | — |
| Site 40 | Lakewood | Colorado | 80228 | — |
| Site 8 | Avon | Connecticut | 06117 | — |
| Site 75 | Farmington | Connecticut | 06032 | — |
| Site 33 | New London | Connecticut | 06320 | — |
| Site 32 | Washington D.C. | District of Columbia | 20036 | — |
| Site 10 | Aventura | Florida | 33180 | — |
| Site 27 | Fort Myers | Florida | 33916 | — |
| Site 66 | Melbourne | Florida | 32935 | — |
| Site 61 | Orlando | Florida | 32806 | — |
| Site 1 | West Palm Beach | Florida | 33401 | — |
| Site 82 | Atlanta | Georgia | 30328 | — |
| Site 55 | Decatur | Georgia | 30030 | — |
| Site 70 | Chicago | Illinois | 60654 | — |
| Site 54 | Peoria | Illinois | 61602 | — |
| Site 63 | South Bend | Indiana | 46545 | — |
| Site 13 | Wichita | Kansas | 67226 | — |
| Site 48 | Lexington | Kentucky | 40509 | — |
| Site 57 | Zachary | Louisiana | 70791 | — |
| Site 9 | Baltimore | Maryland | 21093 | — |
| Site 60 | Rockville | Maryland | 20850 | — |
| Site 74 | St Louis | Missouri | 63141 | — |
| Site 35 | Lincoln | Nebraska | 68510 | — |
| Site 72 | Las Vegas | Nevada | 89113 | — |
| Site 24 | Las Vegas | Nevada | 89128 | — |
| Site 18 | New York | New York | 10016 | — |
| Site 38 | Purchase | New York | 10577 | — |
| Site 3 | Raleigh | North Carolina | 27612 | — |
| Site 47 | Winston-Salem | North Carolina | 27103 | — |
| Site 23 | Beachwood | Ohio | 44122 | — |
| Site 69 | Canton | Ohio | 44718 | — |
| Site 71 | Cincinnati | Ohio | 45249 | — |
| Site 19 | Cleveland | Ohio | 44124 | — |
| Site 30 | Columbus | Ohio | 43213 | — |
| Site 81 | Englewood | Ohio | 45322 | — |
| Site 2 | Eugene | Oregon | 97401 | — |
| Site 42 | Philadelphia | Pennsylvania | 19107 | — |
| Site 77 | Pittsburgh | Pennsylvania | 15206 | — |
| Site 43 | Warwick | Rhode Island | 02886 | — |
| Site 58 | Greer | South Carolina | 29650 | — |
| Site 49 | Mt. Pleasant | South Carolina | 29464 | — |
| Site 53 | Chattanooga | Tennessee | 37404 | — |
| Site 59 | Corpus Christi | Texas | 78414 | — |
| Site 76 | Dallas | Texas | 75231 | — |
| Site 31 | Dallas | Texas | 75234 | — |
| Site 17 | Houston | Texas | 77054 | — |
| Site 62 | San Antonio | Texas | 78229 | — |
| Site 50 | Murray | Utah | 84123 | — |
| Site 36 | Sandy City | Utah | 84070 | — |
| Site 7 | Charlottesville | Virginia | 22903 | — |
| Site 68 | Norfolk | Virginia | 23502 | — |
| Site 65 | Richmond | Virginia | 23294 | — |
| Site 22 | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01382719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2014 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01382719 live on ClinicalTrials.gov.